Welcome to our dedicated page for AGTC news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on AGTC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AGTC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AGTC's position in the market.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The company is focused on developing gene therapies for rare diseases and is currently conducting human clinical trials using AAV-based technologies.
AGTC's advanced programs aim to treat conditions like X-linked retinitis pigmentosa and achromatopsia. Interested parties can access audio webcasts of the presentation via the company's website.
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a leader in gene therapies for rare diseases, will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 8:40 AM E.T. Management will engage in a fireside chat, presenting insights on their ongoing clinical trials and advanced gene therapy programs. AGTC's research focuses on inherited retinal diseases, specifically X-linked retinitis pigmentosa and achromatopsia. Interested parties can access audio webcasts at AGTC's investor relations site.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) is sponsoring the Achroma Corp No Roadblocks program, which provides tinted glasses and contact lenses to individuals with achromatopsia (ACHM). This program aims to assist affected individuals in obtaining essential vision aids for bioptic driving, enhancing their independence. ACHM, caused by genetic mutations, results in severe visual impairment and light sensitivity. AGTC is actively developing AAV-based gene therapies for ACHM and other inherited retinal diseases, emphasizing its commitment to improving the quality of life for patients.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has appointed Dr. Yehia Hashad to its Board of Directors, enhancing its leadership team with his extensive experience in pharmaceuticals, particularly in ophthalmology. With over 25 years in the industry, Dr. Hashad has spearheaded drug development strategies, especially in areas of high unmet medical need. His expertise is expected to guide AGTC in advancing its gene therapies targeting rare retinal diseases, positioning the company for significant advancements in its clinical trials.
AGTC announced its Executive Director of Global Patient Advocacy, Jill Dolgin, will participate in a panel at the Envision Virtual Conference East on August 20-21, 2021. The discussion will focus on genetic testing and gene therapy for rare inherited retinal diseases (IRDs). Dr. Dolgin will be joined by other experts to address patient concerns about these therapies. AGTC is involved in clinical trials using AAV-based gene therapies to potentially improve vision for patients with conditions like X-linked retinitis pigmentosa and achromatopsia.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced its participation in several virtual investor conferences. Sue Washer, President & CEO, will engage in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9, 2021, and join a panel on ophthalmic gene therapy at the Wedbush PacGrow Healthcare Conference on August 11, 2021. Additionally, her presentation at the H.C. Wainwright Ophthalmology Conference will be available for on-demand viewing starting August 17, 2021. For further details, audio replays will be accessible on the Company's website.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) will host a virtual R&D Day on July 22, 2021, from 10:00 am to 1:00 pm ET. The event will highlight 12-month data from ongoing Phase 1/2 clinical trials for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM). Key discussions will cover light sensitivity, genetics, and the company’s new 21,000 sq. ft. cGMP manufacturing facility in Florida. AGTC aims to advance therapies for rare retinal diseases and will provide a comprehensive analysis of its clinical and regulatory processes during this webcast.
Applied Genetic Technologies Corporation (AGTC) announced ongoing clinical activities for its ACHM B3 candidate, with dosing expected to complete in August 2021. The company reported positive 12-month data from achromatopsia Phase 1/2 trials, highlighting improvements in visual sensitivity and safety. AGTC plans to advance ACHM B3 to the next clinical stage and is drafting an End-of-Phase 2 briefing for the FDA. However, the ACHM A3 trial didn't show consistent biologic activity, raising concerns. Upcoming data from younger patients may provide further insights.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) is set to release 12-month data from its Phase 1/2 clinical trials on Achromatopsia (ACHM) on June 24, 2021. This data will cover adult and low-dose pediatric patients, specifically addressing the CNGB3 and CNGA3 gene therapies. Management will host a conference call at 8:00 AM ET to discuss the findings. AGTC focuses on gene therapies for rare retinal diseases and aims to improve vision in patients with inherited retinal conditions. The trial results could significantly influence AGTC’s market position.
